Social networks
1,589Activities
Technologies
Entity types
Location
st, Ole Maaløes Vej 3, 2200 København, Denmark
København
Denmark
Employees
Scale: 2-10
Estimated: 47
Engaged corporates
0Added in Motherbase
7 months, 2 weeks agoDeveloping a maternal vaccine for Group B Streptococcus
MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates.
Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability.
Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.
Group B Streptococcal and GBS
We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.